Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Total Current Liabilities (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Total Current Liabilities for 11 consecutive years, with $58.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities rose 8.56% year-over-year to $58.7 million, compared with a TTM value of $58.7 million through Dec 2025, up 8.56%, and an annual FY2025 reading of $58.7 million, up 8.56% over the prior year.
  • Total Current Liabilities was $58.7 million for Q4 2025 at Spyre Therapeutics, up from $46.3 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $232.2 million in Q2 2023 and bottomed at $12.6 million in Q1 2023.
  • Average Total Current Liabilities over 5 years is $45.7 million, with a median of $32.2 million recorded in 2021.
  • The sharpest move saw Total Current Liabilities skyrocketed 1364.09% in 2023, then plummeted 90.47% in 2024.
  • Year by year, Total Current Liabilities stood at $20.1 million in 2021, then fell by 27.24% to $14.7 million in 2022, then soared by 118.19% to $32.0 million in 2023, then soared by 69.05% to $54.1 million in 2024, then rose by 8.56% to $58.7 million in 2025.
  • Business Quant data shows Total Current Liabilities for SYRE at $58.7 million in Q4 2025, $46.3 million in Q3 2025, and $83.1 million in Q2 2025.